Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

SMOFKABIVEN PERIPHERAL EMULSION FOR INFUSION [SIN14287P]

Active ingredients: ALANINE | ARGININE | CALCIUM CHLORIDE DIHYDRATE | FISH OIL, RICH IN OMEGA -3 ACIDS | GLUCOSE MONOHYDRATE | GLYCINE | HISTIDINE | ISOLEUCINE | LEUCINE | LYSINE ACETATE | MAGNESIUM SULPHATE HEPTAHYDRATE | METHIONINE | OLIVE OIL, REFINED | PHENYLALANINE | POTASSIUM CHLORIDE | PROLINE | SERINE | SODIUM ACETATE TRIHYDRATE | SODIUM GLYCEROPHOSPHATE ANHYDROUS | SOYA BEAN OIL, REFINED | TAURINE | THREONINE | TRIGLYCERIDES, MEDIUM CHAIN | TRYPTOPHAN | TYROSINE | VALINE | ZINC SULPHATE HEPTAHYDRATE

View product's general information
Last updated on 9 October 2026

Product Info

SMOFKABIVEN PERIPHERAL EMULSION FOR INFUSION

[SIN14287P]

Product information

Active Ingredient and Strength

ALANINE - 14 G/1,000 ML
ARGININE - 12 G/1,000 ML
CALCIUM CHLORIDE DIHYDRATE - 0.74 G/1,000 ML
FISH OIL, RICH IN OMEGA -3 ACIDS - 30 G/1,000 ML
GLUCOSE MONOHYDRATE - 143 G/1,000 ML
GLYCINE - 11 G/1,000 ML
HISTIDINE - 3 G/1,000 ML
ISOLEUCINE - 5 G/1,000 ML
LEUCINE - 7.4 G/1,000 ML
LYSINE ACETATE - 9.3 G/1,000 ML
MAGNESIUM SULPHATE HEPTAHYDRATE - 2.47 G/1,000 ML
METHIONINE - 4.3 G/1,000 ML
OLIVE OIL, REFINED - 50 G/1,000 ML
PHENYLALANINE - 5.1 G/1,000 ML
POTASSIUM CHLORIDE - 4.48 G/1,000 ML
PROLINE - 11.2 G/1,000 ML
SERINE - 6.5 G/1,000 ML
SODIUM ACETATE TRIHYDRATE - 5.62 G/1,000 ML
SODIUM GLYCEROPHOSPHATE ANHYDROUS - 4.18 G/1,000 ML
SOYA BEAN OIL, REFINED - 60 G/1,000 ML
TAURINE - 1 G/1,000 ML
THREONINE - 4.4 G/1,000 ML
TRIGLYCERIDES, MEDIUM CHAIN - 60 G/1,000 ML
TRYPTOPHAN - 2 G/1,000 ML
TYROSINE - 0.4 G/1,000 ML
VALINE - 6.2 G/1,000 ML
ZINC SULPHATE HEPTAHYDRATE - 0.023 G/1,000 ML

Dosage Form

INJECTION, EMULSION

Manufacturer and Country

FRESENIUS KABI AB - SWEDEN

Registration Number

SIN14287P

Licence Holder

FRESENIUS KABI (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

B05BA10

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

Parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

Dosing

4.2 Posology and method of administration

Posology

The appearance of the product after mixing the 3 chambers is a white emulsion.

The patient’s ability to eliminate lipids and metabolise nitrogen and glucose, and the nutritional requirements should govern the dosage and infusion rate, see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

The dose should be individualised to the patient’s clinical condition, body weight (bw), nutritional and energy requirements, adjusting dosage based upon additional oral/enteral intake.

The nitrogen requirements for maintenance of body protein mass depend on the patient’s condition (e.g. nutritional state and degree of catabolic stress or anabolism).

Adults

The requirements are 0.6–0.9 g amino acids/kg bw/day (0.10–0.15 g nitrogen/kg bw/day) in the normal nutritional state or in conditions with mild catabolic stress. In patients with moderate to high metabolic stress with or without malnutrition, the requirements are in the range of 0.9–1.6 g amino acids/kg bw/day (0.15–0.25 g nitrogen/kg bw/day). In some very special conditions (e.g. burns or marked anabolism) the nitrogen need may be even higher.

Dosage:
The dosage range of 20–40 ml SmofKabiven Peripheral/kg bw/day will provide 0.6–1.3 g amino acids/kg bw/day (corresponds to 0.10–0.20 g nitrogen/kg bw/day) and 14–28 kcal/kg bw/day of total energy (11–22 kcal/kg bw/day of non-protein energy). This covers the need of the majority of the patients. In obese patients the dose should be based on the estimated ideal weight.

Infusion rate:
The maximum infusion rate for glucose is 0.25 g/kg bw/h, for amino acids 0.1 g/kg bw/h, and for lipids 0.15 g/kg bw/h.

The infusion rate should not exceed 3.0 ml/kg bw/h (corresponding to 0.10 g amino acids, 0.21 g glucose and 0.08 g lipids/kg bw/h). The recommended infusion period is 14–24 hours.

Maximum daily dose:
The maximum daily dose varies with the clinical condition of the patient and may even change from day to day. The recommended maximum daily dose is 40 ml/kg bw/day.

The recommended maximum daily dose of 40 ml/kg bw/day will provide 1.3 g amino acids/kg bw/day (corresponding to 0.2 g nitrogen/kg bw/day), 2.8 g glucose/kg bw/day, 1.1 g lipids/kg bw/day and a total energy content of 28 kcal/kg bw/day (corresponding to 22 kcal/kg bw/day of non-protein energy).

Paediatric population

Children (2–11 years)

Dosage:
The dose up to 40 ml/kg bw/day should be regularly adjusted to the requirements of the paediatric patient that varies more than in adult patients.

Infusion rate:
The recommended maximum infusion rate is 3.0 ml/kg bw/h (corresponding to 0.10 g amino acids/kg/h, 0.21 g/glucose/kg/h and 0.08 g lipids/kg/h).

The recommended infusion period is 12–24 hours.

If using the recommended maximum daily dose, the dose should be infused during a period of at least 13 hours to not exceed the recommended maximum infusion rate, except in particular cases.

Maximum daily dose:
The maximum daily dose varies with the clinical condition of the patient and may even change from day to day. The recommended maximum daily dose is 40 ml/kg bw/day. This recommended maximum daily dose of 40 ml/kg bw/day will provide 1.3 g amino acids/kg bw/day (corresponding to 0.2 g nitrogen/kg bw/day), 2.8 g glucose/kg bw/day, 1.1 g lipids/kg bw/day and a total energy content of 28 kcal/kg bw/day (corresponding to 22 kcal/kg bw/day of non-protein energy).

Adolescents (12–16/18 years)

In adolescents, SmofKabiven Peripheral can be used as in adults.

Method of administration
Intravenous use, infusion into a peripheral or central vein.

SmofKabiven Peripheral is available in three pack sizes intended for patients with moderately increased or basal nutritional requirements. To provide total parenteral nutrition, trace elements, vitamins and possibly electrolytes (taking into account the electrolytes already present in SmofKabiven Peripheral) should be added to SmofKabiven Peripheral according to the patient's need.

For instructions on preparation of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

4.3 Contraindications

  • Hypersensitivity to fish-, egg-, soya- or peanut protein or to any of the active substances or excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information

  • Severe hyperlipidemia

  • Severe liver insufficiency

  • Severe blood coagulation disorders

  • Congenital errors of amino acid metabolism

  • Severe renal insufficiency without access to hemofiltration or dialysis

  • Acute shock

  • Uncontrolled hyperglycaemia

  • Pathologically elevated serum levels of any of the included electrolytes

  • General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, and decompensated cardiac insufficiency

  • Hemophagocytotic syndrome

  • Unstable conditions (e.g. severe post-traumatic conditions, uncompensated diabetes mellitus, acute myocardial infarction, stroke, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration and hyperosmolar coma)

  • Infants and children under 2 years of age